Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023
|出版日||ページ情報||英文 214 Pages
|核医学/放射性医薬品の世界市場予測 ～2023年：種類（診断用（SPECT、PET）、治療用（ベータ放射体、アルファ放射体、小線源療法）、用途（癌、甲状腺、心臓）、地域別 Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023|
|出版日: 2018年06月14日||ページ情報: 英文 214 Pages||
核医学/放射性医薬品の市場規模は、今後5年間（2018年～2023年）に5.9%のCAGR (年間複合成長率) で推移し、2018年に39億5,000万米ドル、2023年に52億6,000万米ドル規模の市場に成長するものと予測されています。癌および心臓病の罹患率・有病率の上昇、医用ラジオアイソトープm-99の需給ギャップ縮小への取組みなどが、今後の核医学/放射性医薬品市場を促進すると予測されています。しかし、放射性医薬品の半減期の短さ、病院予算の削減、高額な医療機器などが、当市場の成長にとって大きな課題となっています。
The nuclear medicine market is projected to reach USD 5.26 billion by 2023 from USD 3.95 billion in 2018. Factors such as the growing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99, are driving market growth. However, the short half-life of radiopharmaceuticals, hospital budget cuts, and high equipment prices are likely to restrain market growth.
Based on type, the nuclear medicine market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. The diagnostic radiopharmaceuticals have been segmented into SPECT and PET radiopharmaceuticals. PET radiopharmaceuticals have been further segmented into F-18, Ru-82, and other PET isotopes. In 2017, the F-18 segment accounted for the largest share of the nuclear medicine PET radiopharmaceuticals market. F-18 is the most commonly used PET radioisotope owing to its higher half-life (110 minutes) compared to other radioisotopes. F-18 is estimated to account for 98% of the total PET radioisotopes market.
The major application areas of SPECT nuclear medicine include cardiology, lymphoma, thyroid, neurology and others (prostate cancer diagnosis, bone scans, and white cell scans). The thyroid applications segment is expected to register the highest CAGR during the forecast period. Growth in this application segment is mainly driven by the rising demand for combinational SPECT/CT therapy owing to its enhanced imaging abilities. Moreover, with growth in the number of thyroid cancer cases, the use of radiopharmaceuticals for diagnosis of thyroid disorders is expected to increase in the next five years.
The nuclear medicine market is divided into four major regions- North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the nuclear medicine market. The major factors contributing to the large share of this segment include the development of novel technologies for radioisotope production, government support, and company initiatives in the region.
Asia Pacific is expected to register the highest CAGR during the forecast period. The major factors driving the growth of this regional segment include research initiatives in Japan and the rising installations of PET scanners in India and China.
Break of primary participants was as mentioned below:
The major market players in the nuclear medicine market include: Cardinal Health (US), GE Healthcare (US), and Curium (France).
The report analyzes the market and aims at estimating the size and the future growth potential of this market based on various segments such as type, application, procedural volume, and region. The report also includes the competitive landscape of the key players along with their company profiles, product offerings, recent developments, and key market strategies.
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned strategies.
This report provides insights on the following pointers:
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.